Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Giulia Roda(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Jean‐Frédéric Colombel(Mount Sinai Hospital), Neeraj Narula(McMaster University), Bindia Jharap(Meander Medisch Centrum)
Clinical and Translational Gastroenterology
January 1, 2016
10.1038/ctg.2015.63
Cited by 724

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
|Nature Genetics|2011|1.4k